This will take effect January 28, 2013
Overview and Clinical Utility:
Effective January 28, 2013, PathGroup will implement in-house testing for Fibrinogen and Factor VIII Activity. Fibrinogen is a coagulation factor (Factor I) produced by the liver, and is essential for blood clot formation. Low levels of fibrinogen are associated with bleeding commonly secondary to liver disease or Disseminated Intravascular Coagulation (DIC). Fibrinogen is an acute phase reactant and elevated levels may be associated with inflammation. Increased concentrations are associated with increased risk of atherosclerosis.
Click Here to read more.